Dr. Billings is a nationally recognized expert on genomic and precision medicine and a board-certified internist and clinical geneticist. Dr. Billings has devoted his career to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as Chief Medical Officer of Life Technologies, Inc. (acquired by Thermo Fisher Scientific, Inc. in March, 2014). He is Executive-in-Residence at Janssen Diagnostics, Johnson&Johnson Inc., and Medical Director, the IMPACT Cancer Care Program, ThermoFisher Scientific Inc. Dr. Billings has served in multiple other roles in industry and government, including as Executive Chairman, Melanoma Diagnostics, Inc., and director of Trovagene, Inc., DecisionQ, Inc. and PAX Neuoscience, Inc. He was Co-Founder and first Medical Director of the Cordblood Registry, Inc., past Senior Physician and SVP of Laboratory Corporation of America, Inc. (LabCorp), Co-Founder and Past Director of Omicia, Inc., Founder and EVP of GeneSage, Inc., and past Director of Ancestry.com, Inc. Dr. Billings has served on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. Dr. Billings has held academic appointments at prestigious universities including Harvard University, UCSF, Stanford University and UC Berkeley, and has served as a physician at numerous medical centers. He is the author of over 200 publications, abstracts and books on experimental and clinical medicine. Dr. Billings holds an M.D. degree from Harvard Medical School and a Ph.D. degree in Immunology from Harvard University.